Table III.
Underlying conditions in patients exposed to VZV infection
| Underlying conditions | Total (n, %) (n=117) |
PEP (n, %) (n=107) |
Non-PEP (n, %) (n=10) |
|
|---|---|---|---|---|
| Primary disorder | Hematological malignancy | 41 (35.0) | 38 (35.5) | 3 (30.0) |
| Solid tumor | 62 (53.0) | 56 (52.3) | 6 (60.0) | |
| Primary immunodeficiency | 6 (5.1) | 6 (5.6) | 0 (0) | |
| Others | 8 (6.8) | 7 (6.5) | 1 (10.0) | |
| Chemotherapy | 71 (60.7) | 63 (58.9) | 8 (80.0) | |
| Immunosuppressive therapy | 46 (39.3) | 43 (40.2) | 3 (30.0) | |
| Transplantation | Hematopoietic stem cell | 30 (25.6) | 28 (26.2) | 2 (20.0) |
| Liver | 8 (6.8) | 8 (7.5) | 0 (0) |
VZV, Varicella-Zoster virus; PEP, post-exposure prophylaxis.